Novartis Agrees $12 Billion Biotech Deal for Avidity
Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc. in a deal valued at $12 billion, making it the Swiss drugmaker’s biggest acquisition in more than a decade and...
By Bloomberg · Bloomberg
Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc. in a deal valued at $12 billion, making it the Swiss drugmaker’s biggest acquisition in more than a decade and adding several potential blockbuster treatments as generic competition looms for its current top-sellers. Sam Fazeli of Bloomberg Intelligence has more.